Abstract:Representative studies concerning the pharmacology of traditional medicine and active herbal products have been summarized over the past 12 months.This annual integrative pharmacology review encompasses research articles published during 2019 on the bioactive compounds and extracts used in traditional medicine.Reports highlighting the pharmacology progress of traditional medicine were specifically introduced,including artemisinin for cancer cell sensibility and induction to ferroptosis,rutin for neuroinflammation suppression,Ginseng Radix et Rhizoma for gut microbiota regulation against obesity,green tea and Pu-erh tea for metabolic syndrome,and marine-derived oligosaccharide (GV-971) from brown algae for anti-dementia.Moreover,novel TCM molecular targets and pharmacological mechanisms were trialed against different human diseases,including cancers,cardiovascular,cerebrovascular diseases,diabetes,and metabolic diseases.Notably,herb-derived bioactive products have become important treatment alternatives for cancer research in 2019.Cardiovascular and cerebrovascular diseases,together with diabetes and metabolic diseases,are ongoing research areas for traditional medicine.Moreover,inflammation and infectious disease are also attracting more attention by researchers,which might have been influenced by seasonal influenza or HIV/Ebola viral infections.Further traditional medicine investigations are required in neurodegenerative diseases,depression,and mental diseases.Taken together,the findings of the integrative pharmacology review in 2019 provide a vast number of novel lead compounds or drug candidates for future clinical agent development and also details a novel series of attractive therapeutic targets and molecular mechanisms for human diseases.

Annual Advances of Integrative Pharmacology in 2019